HedyLKindlerMD

Gastrointestinal Cancer, Hematologic Oncology, Thoracic Cancer

Professor of Medicine, University of Chicago

Overview of Dr. Kindler

Dr. Hedy Kindler is an oncologist in Chicago, IL and is affiliated with University of Chicago Medical Center. She received her medical degree from University at Buffalo School of Medicine and has been in practice 28 years. Dr. Kindler accepts several types of health insurance, listed below. She is one of 123 doctors at University of Chicago Medical Center who specialize in Oncology. She has more than 100 publications and over 500 citings.

Office
5841 S. MARYLAND
M/C 2115
Chicago, IL 60637
Book by Phone+1(877) 791-4161

Fax+1 773-702-3163
Is this information wrong?

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1992 - 1995
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 1991 - 1992
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 1989 - 1991
Jacobs School of Medicine and Biomedical Sciences at the University at BuffaloClass of 1989

Certifications & Licensure

IL State Medical License 1998 - 2026
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Chicago Magazine: Top Doctors Castle Connolly, 2008, 2010, 2012, 2014, 2016
America's Top Doctors Castle Connolly, 2009-2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer Start of enrollment: 1996 Nov 01
Completed
Phase 1
Aminocamptothecin in Treating Patients With Stomach Cancer or Cancer of the Esophagus Start of enrollment: 1998 Mar 01
Completed
Phase 2
Dolastatin 10 in Treating Patients With Metastatic Or Recurrent Liver, Bile Duct, or Gallbladder Cancer Start of enrollment: 1999 Jan 01
Completed
Phase 2
Dolastatin 10 in Treating Patients With Metastatic Pancreatic Cancer Start of enrollment: 1999 Feb 01
Completed
Phase 2
Irofulven in Treating Patients With Metastatic or Recurrent Colorectal Cancer Start of enrollment: 1999 Apr 01
Withdrawn
Phase 2
Irinotecan and Cyclosporine in Treating Patients With Metastatic, Advanced or Locally Recurrent Colorectal Cancer Start of enrollment: 2000 Jan 01
Completed
Phase 2
Capecitabine in Treating Patients With Malignant Mesothelioma Start of enrollment: 2000 Nov 01
Completed
Phase 2
SU5416 in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer Start of enrollment: 2000 Aug 01
Terminated
Phase 2
SU5416 in Treating Patients With Malignant Mesothelioma Start of enrollment: 2000 Aug 01
Completed
Phase 2
BMS-247550 in Treating Patients With Recurrent or Metastatic Colorectal Cancer Start of enrollment: 2001 Sep 01
Completed
Phase 2
BMS-247550 in Treating Patients With Liver or Gallbladder Cancer Start of enrollment: 2001 Aug 01
Terminated
Phase 2
Oxaliplatin With or Without Gefitinib in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer Start of enrollment: 2001 Sep 01
Completed
Phase 1, Phase 2
Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma Start of enrollment: 2001 Oct 01
Completed
Phase 2
Bevacizumab and Gemcitabine in Treating Patients With Advanced Pancreatic Cancer Start of enrollment: 2002 Feb 01
Completed
Phase 2
Arsenic Trioxide in Treating Patients With Pancreatic Cancer That Has Not Responded to Gemcitabine Start of enrollment: 2003 Feb 01
Completed
Phase 2
PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma Start of enrollment: 2003 Jul 01
Completed
Phase 2
Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Start of enrollment: 2004 Jun 01
Completed
Phase 3
Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Start of enrollment: 2004 Sep 01
Completed
Phase 2
Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma Start of enrollment: 2004 Feb 01
Completed
Phase 2
Study of CAP1-6D in Patients With Locally Advanced or Surgically Resected Pancreatic Adenocarcinoma Start of enrollment: 2003 Apr 01
Completed
Phase 1, Phase 2
Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate Start of enrollment: 2005 Sep 14
Active, not recruiting
Phase 2
An Efficacy Study of Milataxel (TL139) Administered Orally for Malignant Mesothelioma Start of enrollment: 2008 Mar 01
Unknown status
Phase 2
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer Start of enrollment: 2009 Sep 01
Completed
Phase 1, Phase 2
FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma Start of enrollment: 2011 Aug 23
Completed
Phase 1
Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Surgery or Biopsy Start of enrollment: 2008 Jul 02
Suspended
Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Start of enrollment: 2012 Apr 18
Active, not recruiting
Phase 2
Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma Start of enrollment: 2012 Jun 01
Completed
Phase 2
Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies Start of enrollment: 2012 Mar 26
Completed
Phase 1
Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling Start of enrollment: 2013 Oct 09
Completed
Phase 1
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma Start of enrollment: 2013 Sep 01
Terminated
Phase 2
Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting Start of enrollment: 2014 Feb 05
Completed
Phase 2
Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy Start of enrollment: 2014 Dec 16
Active, not recruiting
Phase 3
PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression Start of enrollment: 2015 Jan 20
Completed
Phase 2
Pembrolizumab in Treating Patients With Malignant Mesothelioma Start of enrollment: 2015 Mar 31
Active, not recruiting
Phase 2
Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM) Start of enrollment: 2015 Dec 03
Completed
Phase 2
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) Start of enrollment: 2015 Dec 18
Recruiting
Phase 2
Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors Start of enrollment: 2016 Feb 03
Completed
Phase 1
A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma Start of enrollment: 2016 Feb 25
Recruiting
Phase 1
A Study of LY2510924 and Durvalumab in Participants With Solid Tumors Start of enrollment: 2016 Sep 01
Terminated
Phase 1
Perioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot Study Start of enrollment: 2016 Jun 28
Terminated
Phase 1
Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery Start of enrollment: 2017 Mar 24
Active, not recruiting
Phase 2
A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib Start of enrollment: 2019 Feb 11
Active, not recruiting
Phase 3
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas Start of enrollment: 2018 Oct 10
Recruiting
Phase 1
Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced Pancreatic Cancer Start of enrollment: 2019 May 10
Active, not recruiting
Phase 3
A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer Start of enrollment: 2020 Jan 31
Recruiting
Phase 3
Olaparib in Patients With HRD Malignant Mesothelioma Start of enrollment: 2021 Feb 19
Recruiting
Phase 2
Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression Start of enrollment: 2019 Apr 16
Recruiting
Phase 1, Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

A phase II study of bevacizumab and temsirolimus in advanced extra-pancreatic neuroendocrine tumors.
Sonia M Abuzakhm, Vineeth Sukrithan, Briant Fruth, Rui Qin, Jonathan Strosberg, Timothy J Hobday, Thomas Semrad, Diane Reidy-Lagunes, Hedy Lee Kindler, George P Kim, J...> ;Endocrine-Related Cancer. 2023 Nov 1
The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Updated Modeling of Prognostic Factors in Pleural Mesothelioma.
Andrea S Wolf, Adam Rosenthal, Dorothy J Giroux, Anna K Nowak, Andrea Bille, Marc de Perrot, Hedy L Kindler, David Rice, Isabelle Opitz, Valerie W Rusch, Harvey I Pass, > ;Journal of Thoracic Oncology. 2023 Aug 9
Germline Variants Incidentally Detected via Tumor-Only Genomic Profiling of Patients With Mesothelioma.
Owen D Mitchell, Katie Gilliam, Daniela Del Gaudio, Kelsey E McNeely, Shaili Smith, Maria Acevedo, Meghana Gaduraju, Rachel Hodge, Aubrianna S S Ramsland, Jeremy Segal...> ;JAMA Network Open. 2023 Aug 1
Characterizing the distribution of alterations in mesothelioma and their correlation to morphology.
Heather I-Hsuan Chen-Yost, Melissa Y Tjota, Guimin Gao, Owen Mitchell, Hedy Kindler, Jeremy Segal, Aliya N Husain, Jeffrey Mueller, Jefree J Schulte> ;American Journal of Clinical Pathology. 2023 Sep 1
Surgical phenotype of patients with peritoneal mesothelioma and a germline mutation.
Yaniv Berger, Meghana Gadiraju, Ankit Dhiman, Katie Gilliam, Buerkley Opalecky, Heather Chen, Maria Helgeson, Oliver S Eng, Aliya N Husain, Michael W Drazer, Hedy L Ki...> ;Cancer. 2023 Jul 15
1 citations
Management of Patients With Pancreatic Cancer Using the "Right Track" Model.
Allison Rosenzweig, Jordan Berlin, Suresh Chari, Hedy Kindler, Lynn Matrisian, Allison Mayoral, Jeannine Mills, Nicholas Nissen, Vincent Picozzi, Fatima Zelada-Arenas,...> ;The Oncologist. 2023 Jul 5
Patient-centered outcomes in the POLO study of active maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.
Hedy L Kindler, Hyun Kyoo Yoo, Robert Hettle, Karen Y Cui, Seongjung Joo, Gershon Y Locker, Talia Golan> ;Cancer. 2023 May 1
Outcomes of Universal Point-of-Care Genetic Testing in Diverse Patients With Pancreatic Ductal Adenocarcinoma.
Christine M Drogan, Hedy L Kindler, Guimin Gao, Sonia S Kupfer> ;JCO Precision Oncology. 2023 Jan 1
A population-based evaluation of tunica vaginalis mesothelioma: An analysis of the National Cancer Database.
Hunter D D Witmer, Ankit Dhiman, Mihai Giurcanu, Oliver S Eng, Scott Eggener, Hedy L Kindler, Kiran K Turaga> ;Urologic Oncology. 2023 Jan 1
ASO Visual Abstract: Phase II Prospective Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy with and without Sequential Cytoreductive Inte...
Ankit Dhiman, Charles C Vining, Hunter D D Witmer, Divya Sood, Ardaman Shergill, Hedy Kindler, Kevin K Roggin, Mitchell C Posner, Osmanuddin S Ahmed, Stanley Liauw, Se...> ;Annals of Surgical Oncology. 2022 Dec 1
23 citations
Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
Hedy L Kindler, Pascal Hammel, Michele Reni, Eric Van Cutsem, Teresa Macarulla, Michael J Hall, Joon Oh Park, Daniel Hochhauser, Dirk Arnold, Do-Youn Oh, Anke Reinache...> ;Journal of Clinical Oncology. 2022 Dec 1
18 citations
Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations.
Michele Carbone, Harvey I Pass, Guntulu Ak, H Richard Alexander Jr, Paul Baas, Francine Baumann, Andrew M Blakely, Raphael Bueno, Aleksandra Bzura, Giuseppe Cardillo, ...> ;Journal of Thoracic Oncology. 2022 Jul 1
Marital Status, Living Arrangement, and Cancer Recurrence and Survival in Patients with Stage III Colon Cancer: Findings from CALGB 89803 (Alliance).
Seohyuk Lee, Chao Ma, Sui Zhang, Fang-Shu Ou, Tiffany M Bainter, Donna Niedzwiecki, Leonard B Saltz, Robert J Mayer, Renaud Whittom, Alexander Hantel, Al Benson, Danie...> ;The Oncologist. 2022 Jun 8
5 citations
Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies.
Sherin Juliet Rouhani, Jovian Yu, Daniel Olson, Yuanyuan Zha, Apameh Pezeshk, Alexandra Cabanov, Athalia R Pyzer, Jonathan Trujillo, Benjamin A Derman, Peter O'Donnell...> ;Journal for Immunotherapy of Cancer. 2022 Jun 1
1 citations
Systemic Therapy for Mesothelioma: Turning the Corner.
Hedy Lee Kindler> ;JCO Oncology Practice. 2022 Jun 1
The role of imaging in diagnosis and management of malignant peritoneal mesothelioma: a systematic review.
Bradley Carlson, Carla Harmath, Kiran Turaga, Hedy L Kindler, Samuel G Armato 3rd, Christopher Straus> ;Abdominal Radiology. 2022 May 1
8 citations
Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial.
Hedy L Kindler, Silvia Novello, Alessandra Bearz, Giovanni L Ceresoli, Joachim G J V Aerts, James Spicer, Paul Taylor, Kristiaan Nackaerts, Alastair Greystoke, Ross Je...> ;The Lancet. Oncology. 2022 Apr 1
8 citations
Diet- and Lifestyle-Based Prediction Models to Estimate Cancer Recurrence and Death in Patients With Stage III Colon Cancer (CALGB 89803/Alliance).
En Cheng, Fang-Shu Ou, Chao Ma, Donna Spiegelman, Sui Zhang, Xin Zhou, Tiffany M Bainter, Leonard B Saltz, Donna Niedzwiecki, Robert J Mayer, Renaud Whittom, Alexander...> ;Journal of Clinical Oncology. 2022 Mar 1
1 citations
Associations Between Unprocessed Red Meat and Processed Meat With Risk of Recurrence and Mortality in Patients With Stage III Colon Cancer.
Erin L Van Blarigan, Fang-Shu Ou, Tiffany M Bainter, Charles S Fuchs, Donna Niedzwiecki, Sui Zhang, Leonard B Saltz, Robert J Mayer, Alexander Hantel, Al B Benson 3rd,...> ;JAMA Network Open. 2022 Feb 1
1 citations
Phase II Prospective, Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy With and Without Sequential Cytoreductive Interventions for Patien...
Ankit Dhiman, Charles C Vining, Hunter D D Witmer, Divya Sood, Ardaman Shergill, Hedy Kindler, Kevin K Roggin, Mitchell C Posner, Osmanuddin S Ahmed, Stanley Liauw, Se...> ;Annals of Surgical Oncology. 2022 Jan 5
Correction: Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients.
Julia C F Quintanilha, Jin Wang, Alexander B. Sibley, Chen Jiang, Amy S. Etheridge, Fei Shen, Guanglong Jiang, Flora Mulkey, Jai N. Patel, Daniel L. Hertz, Elizabeth C...> ;British Journal of Cancer. 2021 Dec 1
41 citations
Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial.
Patrick M. Forde, Valsamo Anagnostou, Z. Sun, Suzanne E. Dahlberg, Hedy L. Kindler, Noushin Niknafs, Thomas Purcell, Rafael Santana-Davila, Arkadiusz Z. Dudek, Hossein...> ;Nature Medicine. 2021 Nov 8
5 citations
Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients.
Julia C F Quintanilha, Jin Wang, Alexander B. Sibley, Chen Jiang, Amy S. Etheridge, Fei Shen, Guanglong Jiang, Flora Mulkey, Jai N. Patel, Daniel L. Hertz, Elizabeth C...> ;British Journal of Cancer. 2021 Oct 6
5 citations
Genome-wide association studies of survival in 1520 cancer patients treated with bevacizumab-containing regimens
Julia C F Quintanilha, Jin Wang, Alexander B. Sibley, Wei Xu, Osvaldo Espin-Garcia, Chen Jiang, Amy S. Etheridge, Mark J. Ratain, Heinz-Josef Lenz, Monica M. Bertagnol...> ;International Journal of Cancer. 2022 Jan 15
1 citations
Understanding the new therapeutic options for mesothelioma.
Hedy L. Kindler> ;The Lancet. Oncology. 2021 Sep 6
Join now to see all

Journal Articles

Dynamic Contrast-Enhanced CT for the Assessment of Tumour Response in Malignant Pleural Mesothelioma: A Pilot Study
Hedy L Kindler, Christopher M Straus, European Radiology

Other

A Glimmer of Hope for Pancreatic Cancer
Hedy Kindler, MD, The New England Journal of Medicine
https://www.doximity.com/articles/4da358e8-3072-4a10-8624-6ba76937ef66
UpToDate, Wolters Kluwer Health - 2012-08-30

Authored Content

Phase II Trial of Veliparib in Patients with Previously Treated BRCA-Mutated Pancreas Ductal Adenocarcinoma☆January 2018

Press Mentions

Top Mesothelioma Cancer Center in Chicago Adding New FacilityMarch 22nd, 2022
Added Anti-VEGFR2 Antibody Boosts Survival in MesotheliomaSeptember 8th, 2021
Mesothelioma Olaparib Clinical Trial Targets Genetic MutationAugust 24th, 2021
Join now to see all

Grant Support

NCI National Clinical Trials Network Lead Academic Participating SiteNIH2014–2019
PI3K as a Therapeutic Target in Malignant Pleural MesotheliomaDepartment of Defense2012–2014
Cancer And Leukemia Group BNational Cancer Institute2009–2012
Novel Targeted Therapy In Pancreatic CancerNational Cancer Institute2009–2010

Professional Memberships

Hospital Affiliations

University of Chicago Medical CenterChicago, Illinois

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS Illinois BlueChoice Select
BCBS Illinois PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Cofinity PPO
Coventry Health Care PPO Platinum
Coventry Missouri - HMO/POS
First Health PPO
Great West PPO
HealthLink PPO
Multiplan PHCS PPO
Multiplan PPO
Sagamore Health Plus
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment